Entering text into the input field will update the search result below

Biotech-WAR$ - Raise A Hallelujah

Nov. 09, 2019 6:45 PM ETAbbVie Inc. (ABBV), ABT, AMGN, AMRN, AZN, BGNE, BIIB, BMRN, BMY, GILD, ILMN, ISRG, JNJ, LLY, MDT, MRK, NVO, NVS, PFE, REGN, RHHBY, VRTXABMD, AGN, CELG, VAR
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Summary

  • Politicos are now simultaneously spearheading Biotech-WAR$™, Tech WARS, and now Class WARS.
  • The biotech/medtech sectors continue to succeed and are on track to have another banner 2019 both in product development and financial success.
  • Billionaire Leon Cooperman has had enough and is fighting back.
  • Google and Facebook and Twitter should all fight back as should every Biotech company, every Bank, every business in the America.

Politicos have expanded their “Enemies of the States” targets beyond the biotech companies as they are now expanding their attacks to other selected groups i.e., wealthy/successful Americans, successful American High-Tech companies like Google, Facebook, Twitter and every American with any type of wealth, especially American Billionaire’s. Politicos are now simultaneously spearheading Biotech-WAR$™, Tech WARS, and now Class WARS, and openly attacking all businesses, especially those that have widespread social links all for their political advantage. Who will the next “others” group/” Enemies of the States” be?

Price tag for Warren's universal healthcare: $20.5T

Ultra-Millionaire Tax

Elizabeth Warren shares a 'calculator for billionaires' for her wealth tax plan

Billionaire Leon Cooperman has had enough with regard to the onslaught of ‘politico’ attacks on wealthy Americans and is fighting back. Good for him, and it is good to see him do this. Google and Facebook and Twitter should all learn from this and fight back as should every Biotech company, every Bank, every business in the America.

Leon Cooperman rips Elizabeth Warren in new letter for 'soak-the-rich positions,' and treating him like 'an ungrateful child'

Meanwhile, and irrespective of all the political clatter, the biotech/medtech sectors continue to succeed and are on track to have another banner 2019 both in product development and financial success. The progress and clinical successes of new meds in late October 2019 and early November 2019 have been extraordinary. Highlighted below are a few recent notable biotech/medtech newsworthy press releases;

Genentech's Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials

Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting¹

Harmony® Test: The first non-invasive prenatal test approved by Health Canada

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Takeda's Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

CALQUENCE® Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting

Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

Alibaba Deepens Health Care Interest With Stake in Private Clinic Operator

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

AstraZeneca to Present Pivotal Roxadustat Phase III Data at the American Society of Nephrology Kidney Week 2019

Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet

FDA Accepts Genentech's Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Fosun Dives Deeper Into Health Sector With International Investment Alliance

RINVOQ™ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis

Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Caixin New Economy Index Rebounds on Rising Capital, Tech Inputs

Glaxo's TB vaccine shows positive effect in mid-stage study; shares up 1%

Bethel Music - Raise A Hallelujah (Official Lyric Video) VICTORY

•Jan 24, 2019 Bethel Music

Bethel Music - Raise A Hallelujah (LIVE) | VICTORY

Respectfully submitted to Seeking Alpha on November 9, 2019. As of 11/9/19 I remain 100% invested in biotech and medtech companies. And I remain long all companies noted below;

(MRK) (BMY) (CELG) (PFE) (LLY) (AMGN) (GILD) (AMRN) (VRTX) (BGNE) (ABBV) (AZN) (NVS) (NVO) (MDT) (JNJ) (ABMD) (VAR) (ABT) (BIIB) (REGN) (ILMN) (OTCQX:RHHBY) (BMRN) (AGN) (SGEN) (ISRG)

The SeekingBiotechAlpha portfolio is here =

seekingbiotechalpha.com | danwatson888's Portfolio on GuruFocus.com

The SeekingBiotechAlpha top stock picks are here =

https://seekingbiotechalpha.com/biotech

investments of seeking biotech alpha as of 11/9/2019

www.seekingbiotechalpha.com

So, Raise A Hallelujah & Sing a Little LOUDER

GLTA Dan Watson

https://danwatson.com/

Analyst's Disclosure: I am/we are long ABBV, AZN, AMGN, BMY, PFE, MRK, LLY, CELG.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.
ABT--
Abbott Laboratories
AMGN--
Amgen Inc.
AMRN--
Amarin Corporation plc
AZN--
AstraZeneca PLC